Benefits of PDE7 inhibitors were reported in the treatment of experimental autoimmune encephalomyelitis (EAE) in mice, as an animal model of human multiple sclerosis [52,55,57,58,59,60], spinal cord injury [61], a murine model of Alzheimer’s disease [62,63], a rodent model of Parkinson’s disease [64,65], as well as in sevoflurane-induced long-term memory deficits in mice [66]. The gene discussed is PDE7A; the disease is multiple sclerosis.